Vigabatrin in epilepsy in mentally retarded patients.

Matilainen, Riitta; Pitkänen, A.; Ruutiainen, T; Mervaala, Esa; Riekkinen, P.

doi:10.1111/j.1365-2125.1989.tb03471.x

Cited by 21 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agitation, hyperactivity and insomnia in addition to drowsiness seem to be the most frequent adverse effects of vigabatrin in children (Livingston et al 1989;Luna et al 1989;Uldall et al 1991). The same complaints have been noted in mentally retarded adult patients (Matilainen et a/. 1988;Luna et al 1989).…”

Section: Tolerability Adverse Effectssupporting

confidence: 76%

“…Ben-Menachem et al (1989) described a reduction of paroxysmal activity in 6 of 13 patients experiencing a reduced seizure frequency. Several other studies showed no significant changes in the EEG during vigabatrin treatment (Tartara et al 1986;Tassinari et al 1987;Matilainen et al 1988).…”

Section: Clinical and Laboratory Safety Testsmentioning

confidence: 93%

“…In patients with refractory epilepsy in addition to mental retardation more than 50% seizure reduction was found in 43% of the patients with seizures of partial onset and in 33% of the patients with primary generalized epilepsy (Matilainen et al 1988). This result is almost concordant to the efficacy of vigabatrin in patients without severe handicap.…”

Section: Clinical Efficacy In Mentally Retarded Patientsmentioning

confidence: 99%

“…No influence of vigabatrin on other antiepileptic drugs has been observed (Rimmer & Richens 1984;Loiseau et al 1986;Tartara et al 1986;Browne et al 1987;Tassinari et al 1987;Matilainen et al 1988;Luna et al 1989;Ring et al 1990).…”

Section: Drug Interactionsmentioning

confidence: 99%

See 3 more Smart Citations

Pharmacology of Vigabatrin

Sabers

Gram

1992

Pharmacology & Toxicology

View full text Add to dashboard Cite

Vigabatrin (gamma-vinyl GABA) is a relatively new antiepileptic drug. Vigabatrin increases the concentration of gamma-aminobutyric acid (GABA) in the brain by inhibiting the major GABA metabolizing enzyme, GABA transaminase. Controlled clinical trials have demonstrated an excellent antiepileptic effect of vigabatrin, especially in the treatment of partial epilepsies. Long-term evaluations have shown no signs of tolerance development. Vigabatrin decreases the plasma concentration of phenytoin during concomitant therapy, the only drug with which an interaction seems to occur. In general, vigabatrin is well tolerated. Psychotic reactions occur in 3-6% of patients. Other frequent side effects are sedation and weight increase. Chronic vigabatrin intoxication in animals caused development of intramyelinic oedema, appearing as microvacuoles in brain white matter. No microvacuolation has been observed in humans, even after long-term treatment. Vigabatrin seems a very valuable new antiepileptic drug.

show abstract

Section: Tolerability Adverse Effectssupporting

confidence: 76%

Section: Clinical and Laboratory Safety Testsmentioning

confidence: 93%

Section: Clinical Efficacy In Mentally Retarded Patientsmentioning

confidence: 99%

Section: Drug Interactionsmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacology of Vigabatrin

Sabers

Gram

1992

Pharmacology & Toxicology

View full text Add to dashboard Cite

show abstract

“…Several reports, however, have demonstrated a reduction (about 20-30%) of the plasma concentrations of phenytoin after adding VGB to the therapy (Tartara et al, 1986;Browne et al, 1987; R i m e r and Richens, 1989). No influence of VGB on other AEDs has been observed (hmmer and Richens, 1984;Loiseau et al, 1986;Tartars et af., 1986;Browne et al, 1987;Tassinari et al, 1987;Matilainen et al, 1988;Luna et al, 1989;Ring et al, 1990).…”

Section: Pharmacdogy Vgb Is Rapidly and Almost Completelymentioning

confidence: 99%